December 09, 2022 | The Legal Intelligencer
Cannabis' Plummeting Price-Per-Pound and the Rise of Delta-8 THCAlthough forming America's sixth-largest crop yielding 48.8 million pounds of flower and $27 billion in legal sales annually, marijuana's plunging price-per-pound and the availability of cheaper, unregulated hemp-derived tetrahydrocannabinol (THC) products is thwarting the cannabis industry.
By Steve Schain
10 minute read
November 04, 2022 | The Legal Intelligencer
How Cannabis Is Looking to Conquer NFTs and the MetaverseWhile offering to solve cannabis' most severe woes, it is unclear whether the "shared, immersive virtual world" metaverse's reach exceeds its grasp or whether cryptographic, blockchain asset non fungible tokens are "all flash and no cash."
By Steve Schain
9 minute read
August 25, 2022 | The Legal Intelligencer
Are 'Cannabis Appellations' Malarkey? A Look at Calif.'s New ProgramWhile aspiring to mirror its wine industry counterparts' success and empower small growers to compete in an increasingly challenging marketplace, it is unclear whether a critical mass of consumers is willing to pay a premium price for appellation-containing cannabis or what impact federal marijuana legalization will have on state-based cannabis certification.
By Steve Schain
9 minute read
June 21, 2022 | The Legal Intelligencer
The 'God Molecule'—How Bufo Is Revolutionizing HallucinogensAre hallucinogens' skyrocketing sales arising from a poisonous toad?
By Steve Schain
8 minute read
April 28, 2022 | The Legal Intelligencer
Valuing That Golden Ticket: What's a Marijuana License Actually Worth?Building a cannabis enterprise requires staggering and constant fundraising and, because of the industry's dynamic nature, any given license's value is subjective, fluctuates with external factors beyond the licensee's control, and may change by the minute.
By Steve Schain
9 minute read
March 17, 2022 | The Legal Intelligencer
FDA Addresses Safety Concerns of Cannabis-Derived ProductsBy addressing safety, labeling, misleading claims, and adulteration concerns, DAP enables the FDA to track, authorize and regulate the sale of cannabis-derived products and accelerates CDPs entry into the interstate commerce stream.
By Steve Schain
8 minute read
December 10, 2021 | The Legal Intelligencer
Why the SAFE Banking Act Stinks for MRBsDespite lessening criminal/administrative penalties and depository insurance obstacles, the SAFE Banking Act fails to put legal cannabis on equal footing with all other legitimate industries or make depository accounts and merchant services either available or affordable.
By Steve Schain
10 minute read
August 26, 2021 | The Legal Intelligencer
Obtaining IP Protection for Cannabis Consumer Packaged GoodsHow do you protect intellectual property rights in an insanely lucrative, nearly legal ingredient poised to detonate the consumer packaged goods (CPGs) industry?
By Steve Schain
8 minute read
June 23, 2021 | The Legal Intelligencer
How Delta-8 Hemp Sucker Punched Legalized MarijuanaMirroring legalized marijuana's tetrahydrocannabinol (Delta-9 THC) effects, hemp derived tetrahydrocannabinol (Delta-8 THC) requires no license, is readily available online and over-the-counter, and is cutting into legalized cannabis' $20 billion-plus annual revenue.
By Steve Schain
7 minute read
May 03, 2021 | The Legal Intelligencer
Data-Breach Concerns Rise as NY Launches Adult-Use Cannabis ProgramBecoming the 17th state to legalize adult-use cannabis, on March 31, New York enacted the Marijuana Regulation and Taxation Act (MRTA) anticipated to generate $1.2 billion in annual sales by 2023.
By Steve Schain and Rebecca L. Rakoski
9 minute read
Trending Stories